

119  
**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>o</sup> : <b>C12Q 1/68, 1/04</b>		<b>AI</b>	(11) International Publication Number: <b>WO 99/54502</b>
			(43) International Publication Date: 28 October 1999 (28.10.99)
(21) International Application Number: PCT/NL99/00223		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 19 April 1999 (19.04.99)			
(30) Priority Data: 98201253.6 20 April 1998 (20.04.98) EP			
(71) Applicants <i>(for all designated States except US):</i> ACADEMISCH ZIEKENHUIS GRONINGEN [NL/NL]; Oostersingel 59, NL-9713 EX Groningen (NL); RIJK- SUNIVERSITEIT TE GRONINGEN [NL/NL]; Broerstraat 5, D-9712 CP Groningen (NL).		<b>Published</b> <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants <i>(for US only):</i> JANSEN, Gijsbert, Jo- han [NL/NL]; Suderspaerlaan 16, NL-9061 BJ Giekerk (NL); DEGENER, John, Edward [NL/NL]; de Rozentuin 1, NL-9203 LP Drachten (NL); WELJING, Gjalit, Wietze [NL/NL]; Hoofdstraat 48, NL-9315 PC Roderwolde (NL).			
(74) Agent: OTTEVANGERS, S., U.; Verenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).			

(54) Title: METHOD FOR THE RAPID DETERMINATION OF BACTERIA

(57) Abstract

The invention relates to the detection, identification and diagnosis of bacteria in samples in general and in particular in clinical samples such as blood, urine, saliva, cerebrospinal fluid that are taken from patients that are possibly infected with a, as yet, unknown, possibly pathogenic bacterium, or during follow-up diagnostic testing to, for example, evaluate therapeutic measures that have been taken so far to treat the disease. The invention provides a method for detecting or identifying a bacterium suspected of being present in a sample comprising testing said sample by Gram-staining and testing said sample with a probe according to an *in situ* hybridisation protocol selected on the basis of the outcome of said Gram-staining. The invention also provides probes for use in said method.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	KE	Kenya	NL	Netherlands	VN	Viet Nam
CG	Congo	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CH	Switzerland						
CI	Cote d'Ivoire						
DK	Denmark	UK	United Kingdom	SD	Sudan		
EE	Estonia	UR	Uruguay	SE	Sweden		
				SG	Singapore		

## Title: METHOD FOR THE RAPID DETERMINATION OF BACTERIA

The invention relates to the detection, identification or determination of bacteria in samples in general and in particular in clinical samples such as blood, urine, saliva, cerebrospinal fluid, faeces, pus and tissue that are taken from patients that are possibly infected with a, as yet unknown, possibly pathogenic bacterium, or during follow-up diagnostic testing to for example evaluate therapeutic measures that have been taken so far to treat the disease.

10 Traditional methods to determine or identify bacteria in general start with a Gram stain, which is well known in the art. Such a stain can be performed on a sample immediately after sampling or, when not enough bacteria are present, after a short period of culturing of the sample. In general, four types of bacteria are found after Gram-staining; Gram-negative rods and cocci and Gram-positive rods and cocci. However, such a Gram-stain can only in very exceptional cases provide the clinician with the knowledge required to provide accurate therapy.

20 Examples of Gram-negative rods in clinical samples are *Enterobacter*, *Klebsiella*, *Salmonella*, *Escherichia*, *Proteus* and *Pseudomonas* species, of Gram-negative cocci are *Neisseria* species. Gram-positive rods that may be found in clinical samples are *Bacillus* species, of Gram-positive cocci are *Enterococcus*, *Streptococcus* and *Staphylococcus* species. Some of these, such as *Streptococcus* and *Staphylococcus* can easily be further determined or distinguished from each other by their morphological characteristics. *Streptococci* (and *Enterococci*) are

Streptococcus species cannot be distinguished by morphology alone. However, such relatively rough taxonomic distinction on a genus level cannot be considered satisfactory for clinical purposes and consequently further identification is required to establish proper medication. For example in the case of Staphylococcus, these bacteria need to be further distinguished based on their coagulase positive (S. aureus) or coagulase negative (S. haemolyticus and others) character because these two groups require different antibiotic therapy.

In general, the exact species involved is determined by culturing techniques. To fully determine the species of a bacterium present in a clinical sample the following steps are in general required:

- (1) Pre-culturing of the sample in order to amplify the number of bacteria to a level above the lower detection limits of step (2).

- (2) Culturing on selective and non-selective media.

These traditional methods are time consuming. On average, a regular diagnostic procedure takes at least a few hours (minimally 2) of pre-culturing followed by minimally 24 hours of culturing on selective and non-selective media. This implies that it takes at least 26 hours before the clinician obtains a diagnosis on which he or she can select appropriate antibiotics or base other further treatment.

This latency-period between the sampling of a patient and the final diagnosis is most cases critical for the treatment and the speed-of-recovery of the patient. During this latency-period a patient is in general treated with broad-spectrum antibiotics. The antibiotic of choice is mainly determined by the "clinical eye" of the clinician.

By selecting a broad-spectrum antibiotic, such

is affected also. This side-effect heavily decreases the patient's defence against microbial invaders from the environment. Especially the lowering of the colonisation threshold of the gastro-intestinal tract may cause severe overgrowth by e.g. yeasts and fungi. The resulting secondary infection, or super-infection, in septicæmic patients who already suffer from a decreased immunity often leads to life-threatening situations.

Apart from the serious danger to the patient's health, wide-spectrum antibiotic therapy poses another threat. The repeated exposure of indigenous bacteria to antibiotics enhances the emergence of resistance against such an antibiotic. Especially when a resistance-gene is encoded on a plasmid, other (potential pathogenic) bacterial species may become resistant after the uptake of the plasmid. This latter scenario is considered to be a major problem in hospital epidemiology. It is therefore of paramount therapeutic and epidemiological importance to speed up the methodological procedures in the diagnosis of blood samples from for example septicæmic patients to be able to select specific antibiotic therapy designed for the specific pathogen found, thereby refraining from using broad-spectrum antibiotics.

Present techniques other than culturing, albeit in general specific when beforehand knowledge exists about the species involved, cannot be used with samples containing uncharacterised species, and do thus not fit the acute needs when speedy diagnosis is needed on uncharacterised patient material. In general, these methods are also too slow to meet the needs of the clinician in providing care to his or her patients. Most, for example, require isolation of nucleic acid, or amplification of nucleic acid, or both, before the actual

identify the pathogen and rapidly select the antibiotic against which the pathogen is not resistant. To do this, the micro-organism would again have to be cultured, to determine its resistance pattern, thereby again

5 introducing a lag in diagnosis.

In short, there is a need for fast and reliable diagnosis of bacteria, present in for example clinical samples that may replace or add to the currently used culturing techniques.

10

The invention provides a method for determining, detecting or identifying a bacterium suspected of being present in a sample comprising

- a) testing said sample by Gram-staining and
- 15 b) testing said sample with a probe according to an in situ hybridisation protocol selected on the basis of the outcome of said Gram-staining.

Rapid techniques for detecting bacteria and other bacteria in general are known. For example, in situ  
20 hybridisation is a well known technique, however, in general it has only been applied in specialised laboratories as a tool to detect and quantify the relative abundance of bacteria that are difficult to culture using traditional methodology or as a tool to quantify for  
25 example growth kinetics of already known bacteria in culture.

In short, in in situ hybridisation, nucleic acid probes, labelled with a reporter molecule such as an enzyme or a fluorescing substance, are reacted with  
30 specific nucleic acid sequences found specifically and preferably solely in the bacteria under study, which for this purpose has been permeabilised to let the probe enter the organism. A target sequence such as a

part of a gene or a plasmid, or a specific ribosomal RNA

23S ribosomal RNA, mitochondrial RNA, messenger RNA and nuclear DNA.

In situ hybridisation has never been successfully applied for rapid detection of bacteria in clinical samples because the presently used in situ hybridisation techniques are too inaccurate and too slow to give an advantage over traditional culturing.

First of all, hybridisation requires permeabilisation of the pathogen, and until now no generally applicable permeabilisation protocols have been developed that allow sufficient but restricted lysis of many or all of a broad range of unidentified bacteria. In general, mild permeabilisation leaves many bacteria (such as *Staphylococcus spec.*) inaccessible for subsequent hybridisation with probes, whereas rigorous permeabilisation often fully lyses most bacteria, thereby foregoing the possibility to detect them all together.

In addition, current protocols are in general time-consuming multi-step procedures; hybridisation often requires minimally 24 hours, thereby giving no relief to the needs of the clinician who is only helped with accurate and speedy diagnosis. Furthermore, they mostly require beforehand knowledge about the genus or even species involved in order to select appropriate probes; having such beforehand knowledge is clearly not the case in the event of a patient having an unidentified infection. Also, the present, already inappropriate hybridisation techniques do not allow to gather information on the response against antibiotics of the bacterium involved.

The invention provides a fast and reliable method for diagnosis, detection and/or determination of bacteria which may be present in a sample. Such a sample may be of

from a (contaminated) bacterial culture, or drinking water or food suspected to be contaminated with a bacterium.

In a preferred embodiment the invention provides a method to detect or identify a bacterium suspected of  
5 being present in a clinical sample. Herein, the term "clinical sample" comprises a sample obtained or derived from an animal, preferably a mammal, more preferably a human being. Such a sample may be sampled or tested because a bacterial infection or disease is suspected.  
10 Such a sample can be of various origin, such as blood, serum, white blood cells, cerebrospinal fluid, synovial fluid, tissue, biopsies, urine, saliva, faeces, and others. In a preferred embodiment the invention provides a method wherein said sample is mammalian blood, preferably  
15 being derived from a human.

A sample can be a primary sample or it can be a secondary or sub-sample which is derived from a primary sample by diluting, splitting or culturing it one or more times. Diluting allows determining the relative abundance  
20 of a bacterium in a sample, thereby thus providing a method allowing not only qualitative but also quantitative determination of a bacterium. A sample can be tested directly after it has been obtained or after it has been stored, for example by cooling or freezing and secondary  
25 or sub-samples can be tested in parallel or subsequent from each other.

The invention provides a method comprising determining by Gram-staining the Gram-positive or Gram-negative and rod or coccus type of bacterium in a clinical  
30 sample and further testing said sample according to an *in situ* hybridisation protocol selected on the basis of the outcome of said Gram-staining. A primary advantage of a method according to the invention is the speed with which



protocols. For example, Gram-positive Streptococci can now be determined from within about 2-4 minutes, Gram-negative rods from within about 45-60 minutes, if needed, whereas traditional protocols often need a working day or more. In top of that, after a first indication, or even a definitive selection, of a preferred antibiotic for therapy can be given, based on the results of the testing.

A preferred embodiment of the invention is a method for the detection or identification of bacteria in a clinical sample of blood of patients who are suspected to suffer from a septicaemia. In a preferred embodiment a method provided by the invention makes use of labeled probes, such as fluorescently labeled single strand DNA-, RNA- or PNA-probes, directed against specific target sequences on for example the ribosomal RNA of the target bacterium present in the sample.

The invention provides a method wherein classical Gram-staining indicates the presence of a Gram-negative or Gram-positive bacterium in said sample, further comprising determining the rod or coccus character of said bacterium, thereby establishing the subsequent testing protocol.

When a Gram-negative bacterium is of the rod type, the invention provides a method further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found in *Escherichia coli*, in *Klebsiella pneumoniae*, in *Klebsiella oxytoca*, in *Serratia marcescens*, in *Enterobacter aerogenes*, in *Enterobacter cloacae*, in *Proteus vulgaris*, in *Proteus mirabilis*, in *Salmonella typhi*, in *Pseudomonas aeruginosa*.

Furthermore, the invention provides a method wherein said character is of the Gram-negative-coccus type, further comprising subjecting said sample to treatment

comprising determining the rod or coccus character of said bacterium, and when said Gram-positive character is of the rod type, further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme and/or  
5    Proteinase K.

In addition, when said character is of the Gram-positive coccus type, a method is provided further comprising determining a chain-like or clump-like character of said bacteria before a hybridisation protocol  
10    is selected. When before mentioned character is chain-like, a method provided by the invention is further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme, and further comprising hybridising said sample with at least one probe selected  
15    from a group of probes capable of hybridising with nucleic acid found in *Enterococcus faecalis*, in *Streptococcus pneumoniae*, in *Streptococcus mitis*, in *Streptococcus viridans*, in *Streptococcus sanguis*, in *Enterococcus faecium*.

In addition, a method is provided wherein said character is clump-like, further comprising subjecting said sample to treatment with a lysis buffer comprising lysostaphin and or Proteinase K, further comprising hybridising said sample with at least one probe selected from a group of  
25    probes capable of hybridising with nucleic acid found in *Staphylococcus aureus*, in *Staphylococcus haemolyticus*, in *Staphylococcus saprophyticus*.

Probes used in a method as provided by the invention can be directed against various target nucleic acid  
30    molecules found in a bacterium which can be used are for example ribosomal RNA, mitochondrial RNA, plasmid DNA, messenger RNA and nuclear DNA. It is also possible to select as target molecules nucleic acid from the above

In a preferred embodiment, a method provided by the invention uses as a target for *in situ* hybridisation a 16S ribosomal RNA molecule. In a particular embodiment of the invention said probe is having no more than five, preferably no more than two mismatches with a probe selected or a group composed of probes having a sequence GCGTGGCAGTTTTGGAAAG or GTAGCGCTACTCGTAAGG or GAGCAAAGGTATTAACTTTACTCCC or GTTAGCGCTTCTTTCTGCG or TTATCCCCCTCTGATGGG or AGAGAAGCAAGCCTTCTCGTGGG or 3CGACTCCTCTTTTTTCGGG or GCTAATGCAGCGCGGATGG or CCGAAGGGGAAGGCTCTA or AGAGAAGCAAGCCTTCTCGTGGGTT, each selected in relation to a method as provided by the invention or in relation to congruent antibiotic sensitivity of a bacterium recognised by said probe.

In addition, a method is provided by the invention that is further comprising hybridising said sample with at least one positive control probe capable of hybridising with nucleic acid found in a majority of bacterial species and/or with at least one negative control probe not being capable of hybridising with nucleic acid found in a majority of bacterial species. Preferably said majority comprises at least 90% of bacterial species, especially with those species found in general with possibly infected (septicaemic) patients. A method as provided by the invention is even more specific and/or sensitive when at least 95%, preferably at least 99% of said species is reactive with said positive control probe or no more than 5%, preferably no more than 1% is reactive with said negative control probe.

Such a positive or negative control probe as provided by the invention is given in the experimental part, in general said positive control probe comprises no more than five mismatches with a probe with the sequence

Furthermore, the invention provides a method with additional value to the clinician in that in said method a probe is selected for its reactivity with one or a group of bacterial genera and/or (sub)species having congruent susceptibility to antibiotic treatment. Such a probe detecting or identifying a bacterium in a sample, preferably a clinical sample, is capable of hybridising with nucleic acid found in a group of bacterial genera and/or species or subspecies such as found with *Staphylococcus* and many other bacteria having congruent susceptibility to antibiotic treatment.

In a preferred embodiment of the invention, such a probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTTCGAATG or GAGCAAAGSTATTAAGTTTACTCCC (i.e. reactive with bacteria for which amoxycillin treatment is most likely effective) or GTAGCCCTACTCGTAAGG (cephalosporin treatment) or GTTAGCCGTCCCTTTCTGG (piperacillin and/or aminoglycoside) or TTATCCCCCTCTGATGGG or GCCACTCCTCTTTTCCGG (amoxycillin) or GCTAATGCAGCGCGGATCC or CCGAAGGGGAAGGCTCTA (vancomycin) or AGAGAAGCAAGCTTCTCGTCCGT or AGAGAAGCAAGCTTCTCGTCCG (flucloxacillin).

In a much preferred embodiment of the invention a one-step procedure is used for both binding target bacteria (in the sample) to a microscopic slide and fixing intracellular structures. In the experimental part, various lysis buffers and fixating technique are provided that utilise such a one-step procedure.

Furthermore, the invention provides a diagnostic test kit comprising means for detecting or identifying a bacterium suspected of being present in a sample using a method according to the invention or using a probe

Applicant's attorney: [illegible]

Instructions for a method comprising *in situ* hybridisation may be added. Optionally, said probes, which can be common nucleic acid or peptide nucleic acid probes, are linked to reporter molecules such as direct fluorescent labels.

5 Other reporter molecules, such as enzymes or radioactive labels are also known.

In addition, said kit may comprise one or more of the necessary buffer solutions, such as lysis buffer or hybridisation, optionally in ready made form, or for  
10 example cover slips and reaction vials. Said kit may fully comprise sets of probes reactive with a wide gamut of (pathogenic) bacteria, optionally characterised by reactivity with bacteria of congruent antibiotic susceptibility, or may comprise sets of probes  
15 specifically directed against bacteria of Gram-positive or -negative, rod, coccus or chain- or clump-like character.

Such a kit may also comprise probes specifically reactive with antibiotic resistance genes, providing a positive identification of least applicable antibiotic  
20 treatment.

The invention is further explained in the experimental part of the description which is not limiting the invention.

## 25 Experimental part

An example of a set of probes specific for the detection of pathogenic bacteria and an example of a new protocol for high-speed *in situ* hybridisation are  
30 presented. The methodology described here is for example used for both a preliminary screening of samples from septicæmic patients or as a full substitute on the basis of which therapeutic decisions are made. The invention

11/000 sample 11/000 sample 11/000 sample

## Components

5 A set of fluorescently labeled oligonucleotide probes designed to hybridize specifically with a group of pathogenic bacteria (i.e. genus-specific probe) or with one specific pathogen (i.e. species-specific probe) or with bacteria with congruent susceptibility or resistance to antibiotics.

10 A protocol for fast in situ hybridization of bacteria present in samples of blood collected from septicemic patients, using the said probes.

15 Oligonucleotide probes designed to hybridize specifically with a group of pathogenic bacteria.

In a particular embodiment of the invention a method provided by the invention is exemplified by making use of 16S rRNA target molecule because a large databank containing 16S rRNA-sequences exists and is freely accessible via the Internet. Labeled probes form an essential part in in situ hybridizations. The present invention provides a set of probes which have been designed in an unexpected novel manner i.e. not based on normal taxonomic principles but rather on their pathological significance. The group of probes which apply to this particular embodiment of the invention have been designed in such a way that they span group(s) of bacteria which are clustered on the basis of presumed congruent sensitivity to antimicrobial agents. Positive identification thus yields direct therapeutic information. Grouping bacteria on the basis of their presumed antibiotic susceptibility results in groups of bacteria, several hundreds of different species.

on the criteria of presumed antibiotic susceptibility patterns is much faster over classical culturing methods that still suffer from phenotypic variability induced by environmental factors. The probes are preferably labelled with enzymatic or fluorescent labels. Current fluorescent labels which are applicable in this invention are:

1. Direct fluorescent labels:
  - Fluorescein-isothiocyanate (FITC)
  - 10 - Tetramethylrhodamine-5-isothiocyanate (TRITC)
  - Texasred™
  - 5(6)-carboxyfluorescein-N-hydroxysuccinimide-ester (FLUOS™)
  - 7-amino-4-methylcoumarin-3-acetic acid (AMCA™)
  - 15 - Phycoerythrin
  - Indocarbocyanine dyes such as Cy3™, Cy5™ and C7™
  - Any other direct fluorescent label
- 2) Indirect fluorescent labels:
  - Enzymes such as alkaline phosphatase or
  - 20 horseradishperoxidase either attached directly or via a C6-thiol linker and used in combination with chemiluminescent substrates like AMPPD (3-(4-methylspiro[adamantane]-4-methoxy-4-(3'-phosphoryloxy)-phenyl-1,2-dioxethane) or fluorescence generating substrates.
  - 25 - Digoxigenin (DIG) in combination with anti-DIG antibodies labeled with:
    - gold particles
    - fluorescent labels
    - Enzymes such as alkaline phosphatase or horseradish
    - 30 peroxidase, optionally in combination with chemiluminescent substrates like AMPPD (3-(4-methylspiro[adamantane]-4-methoxy-4-(3'-phosphoryloxy)-phenyl-1,2-dioxethane) or fluorescence generating substrates.
    - Biotin in combination with streptavidin

- Dinitrophenyl as hapten in combination with appropriate antibodies and labeled just like the anti-DIF antibodies
- Any other indirect fluorescent or enzymatic label

5

Fluorescent labels allow direct microscopic analysis preferably combined with image analysis. For the detection of fluorescent oligonucleotide probes hybridised to ribosomal RNA of the target bacterium, photography can be applied. However quantitation by this method is hampered by the absence of objective criteria by means of which discrimination between hybridized and non-hybridized cells can be performed. Therefore for objective evaluation of probe-specificity, an image analysis system is employed which allows fluorimetric reading of individual bacterial cells.

10

15

A protocol for fast in situ hybridization of bacteria present in samples of blood

20

25

30

Protocols for the detection of rRNA in situ typically utilise both a lytic reagent for permeabilisation of the bacterial cell wall and fixatives to preserve structural and molecular integrity of cellular components. However, the results of such hybridizations are highly dependent on the type, concentration and incubation-time of both the lytic reagent and the fixative. Component 2 of the invention consists of a protocol for in situ hybridization in which both permeabilization and fixation have been optimized for a subsequent hybridization of maximally 2 hours. For this protocol it was important to ensure that the hybridization procedure used was applicable to a wide variety of unidentified bacteria. Differentiated use of lytic reagents could only be based on information obtained from direct Gram-staining of the pre-cultured blood



A optimal lytic reagent can be chosen on the basis of the gram-stain of the pathogen present in the sample of blood. This procedure of differentiated permeabilisation is novel to regular protocols for *in situ* hybridisation in which the permeabilisation is always dedicated to the permeabilisation of one or a defined group of target bacteria. In this new procedure a very wide array of unidentified bacteria can sufficiently be permeabilised without destruction of intracellular structures.

A one-step procedure is used for both binding target bacteria (in the sample) to the microscopic slide and fixing intracellular structures. Procedures presented in the current scientific literature all use multi-step protocols for binding, fixing and dehydration of the bacterial cells in order to condition them for optimal hybridisation.

The hybridisation time is shortened to 2 hours. Regular protocols for *in situ* hybridisation utilise a hybridisation time of minimally 24 hours, rendering them useless for rapid diagnostic applications.

The invention also provides kits for carrying out the rapid detection of bacteria in blood samples according to the invention. Such a kit will usually comprise at least a probe or probes and optionally other reagents such as components for hybridisation-fluid, washing-fluid and permeabilisation-fluid.

Such a kit may be applied in a routine bacteriology laboratory or in a bedside environment, both as a fast screening method or as a full substitute for classical identification methods.

Examples of probe design and development

are found in blood from septicaemic patients. In addition each probe hybridises with a species or a cluster of bacteria which share concordant (but often not identical) antibiotic sensitivity patterns

5	11. Sequence (17-37) <sup>1</sup>	Region <sup>2</sup>	Specificity <sup>3</sup>
	A. GTGGCTGCGGTAGGAGT	V2	Bacterial fungus
	B. AATGCTAGCGGAGGCAGT	n.g.	n. matches
10	C. GTCTGCTAGTTTTCGAATG	V1	Salmonella spp., Klebsiella spp., Enterobacter spp.
	D. GTAGCGCTACTCGTAAGG	V1	E. oxytoca, E. marcescens, Enterobacter spp., Proteus spp.
	E. GAGCAAAAGTATTAACTTTACTGCC	V3	E. coli
15	F. TTATCGCGCTCTGATGGG	V1	E. faecalis
	G. GCTAATGTAGCGCGGATCG	V2	S. aureus, S. haemolyticus
	H. CGGAAGGGGAAGGCTCTA	V2	S. aureus, S. saprophyticus
	I. AGAGAAGCAAGCTTCTCGTCCG	V1	Streptococcus spp.
	J. GTTAGCGGTCGCTTTCTGG	V3	P. aeruginosa
20	K. AGAGAAGCAAGCTTCTCGTCCGT	V2	S. aureus
	L. GCGACTGCTCTTTTTCGG	V2	Enterococcus faecium

<sup>1</sup> Each probe optionally contains an FITC-label at the 5'-end

25 <sup>2</sup> The variable region on the 16S rRNA where the target-sequence of the probe is positioned.

<sup>3</sup> The species or genus which rRNA contains a match with the sequence of the probe.

30 Protocol example.

A newly devised protocol for fast in-situ hybridization of pathogens in blood from septicaemic patients. This version consists of a step-wise version which can directly be used in a laboratory environment.

35 1 Collect a sample of blood from a patient using a vacuum sealed culture bottle.

2 Place the culture bottle in the pre-culturing machine (e.g. BactAlert, Organon Teknika, Durham, NC 27704) to monitor the growth of the pathogen on-line

- 3 After bacterial growth in a sample of blood has been detected, perform a Gram-stain and take out the culture bottle and collect 2 ml. of fluid from the bottle using a syringe.
- 5 4 Using the syringe, put +/- 0.1 ml of this sample on a dehydrated glass slide. And streak out using a slide of glass.
- 5 Dry the slide for 5 minutes on a hotplate (for example at approximately 50°C).
- 10 6 Fix during 5 min. in ethanol(96%):formaldehyde 37. (9:1.)
- 7 Dry the slide for 5 minutes on a hotplate. (Slides can be stored for several months if kept at room temperature in a dry chamber)
- 15 8 Permeabilise **Streptococci** 20 min at 25 °C with lysozyme (1 g/l)
- 9 Permeabilise **Staphylococci** 20 min at 25 °C with Lysostaphin (100 units/ml)
- 10 Rinse the slide with (demineralised) water for 5
- 20 minutes
- 11 Dry the slide for 5 minutes on a hotplate.
- 12 Pipet hybridisation buffer(+SDS)-probe mix ([probe]=10ng/µl). Cover with a coverslip.
- 13 Hybridize 2 hours (for example at 48°C).
- 25 14 Rinse 5 min using hybridisation buffer(-SDS).
- 15 Mount the slide with a coverslip.
- 16 Evaluate the slide.

phosphate buffered saline

- 30 - 8 g/l NaCl
- 0.2 g/l KCl
- 1.44 g/l  $\text{Na}_2\text{HPO}_4$
- 0.24 g/l  $\text{KH}_2\text{PO}_4$

Hybridisation buffer (+SDS)

- 900 ml Milli-Q water
- 51,6 g NaCl
- 2,52 g Tris (hydr.) (pH 7,8) + 0,05 g EDTA
- adjust to pH 7,8
- add 90 ml water
- sterilize 15 minutes
- 10 ml SDS (10% stock)

10 hybridisation buffer (+SDS)

- 900 ml Milli-Q water
- 51,6 g NaCl
- 2,52 g Tris
- adjust to pH 7,8
- 15 - 100 ml Milli-Q water
- sterilize 15 minutes

hybridisation buffer-probe mix

- 10 ng/ul of lyophilized probe in hybridisation buffer

20

lysozyme buffer

- 1,2 g Tris (=100mM)
- 1,86 g EDTA (=50mM)
- add 100 ml of milli-Q
- 25 - adjust to pH 7,8
- 0,05 to 0,2 g lysozyme

lysostaphin buffer

- 1,2 g Tris (=100mM)
- 30 - 1,86 g EDTA (=50mM)
- add 100 ml of milli-Q
- adjust to pH 7,8
- 0,05 to 0,2 g lysostaphin
- dilute & lysostaphin to 0,2 ug/ml in milli-Q

Optionally, in lysis buffer or lysis buffer 1, 2 to 0,2 mg/ml proteinase K is added.

- 5 ethanol-formaldehyde (96:10)
- 1 ml formaldehyde (37%)
- 9 ml ethanol (96%)

#### Validation of probe specificity

- 10 Specificity of probes was tested against the complete RDA-database (<http://rdpwww.life.uiuc.edu:80/rdphome.html>) of 15 august 1996 using the CheckProbe command and was considered sufficient if a no more than five, preferably no more than two mismatches were observed. Furthermore, to
- 15 determine whether the probes could reach their specific target sequence, a reference collection of 20 of the most predominant bacteria in sepsis were hybridised using both the protocol and the probes mentioned here above. The result of this validation is listed in table 2. As can be
- 20 read from this table all probes yield a satisfying hybridisation profile. Using the group-probes C and D it is possible to distinguish between: four groups of gram-negative rods:

- C-positive and D-positive: *Klebsiella oxytoca*,
  - 25 *Enterobacter cloacae* and *Enterobacter aerogenes*
  - C-positive and D-negative: *Klebsiella pneumoniae* and *Salmonella typhi*
  - C-negative and D-positive: *Serratia marcescens* and *Proteus vulgaris*
  - 30 C-negative and D-negative: *Proteus mirabilis*.
- For *Escherichia coli* and *Pseudomonas aeruginosa* two species-specific probes (E and J) have been designed and validated. These probes are optionally included because both *Escherichia* and *Pseudomonas* are notorious pathogens

notorious pathogen. Probe I is a genus-specific probe which can be used in conjunction with probe F because Streptococci and Enterococci share the same morphology, while they require different antimicrobial treatment.

- 5 Using both probes G and H, 4 separate species of Staphylococci can be distinguished:

G-positive and H-positive: Staphylococcus aureus

G-positive and H-negative: Staphylococcus haemolyticus

G-negative and H-positive: Staphylococcus saprophyticus

- 10 G-negative and H-negative: Staphylococcus epidermidis

Probe K is a species-specific-probe for Staphylococcus aureus and can be used to support the results obtained by probes G and H.

Table 2.

Bacterium	A	B	C	D	E	F	G	H	I	J	K
<i>Escherichia coli</i>											
<i>Klebsiella pneumoniae</i>											
<i>Klebsiella oxytoca</i>											
<i>Serratia marcescens</i>											
<i>Enterobacter aerogenes</i>											
<i>Enterobacter cloacae</i>											
<i>Proteus vulgaris</i>											
<i>Proteus mirabilis</i>											
<i>Salmonella typhi</i>											
<i>Pseudomonas aeruginosa</i>											
<i>Enterococcus faecalis</i>											
<i>Enterococcus faecium</i>											
<i>Streptococcus pneumoniae</i>											
<i>Streptococcus mitis</i>											
<i>Streptococcus viridans</i>											
<i>Streptococcus sanguis</i>											
<i>Staphylococcus haemolyticus</i>											
<i>Staphylococcus aureus</i>											
<i>Staphylococcus epidermidis</i>											
<i>Staphylococcus saprophyticus</i>											

Legend: Probecoding see table 1, gray=positive hybridization, white=no hybridization

5

Testing a method in whole-blood samples.

Preliminary testing of a new method in 50 whole blood samples which were found positive upon pre-culturing yielded a correlation of 96% between a method described here and the classical culturing method which was also applied to each of the 50 samples.

10

However, the results of a method described here could be obtained within 3 hours while culturing results took a mean analysis-time of 32 hours.

15

Further practical application

Septicemia is a pathological condition in which viable and multiplying bacteria may be present in the bloodstream.

This condition may occur after trauma or surgery (especially of the visceral organs), immunosuppression and obstetrical complications. It is a potential life-threatening condition and appropriate information on the

20

is routinely carried out by selective culturing of blood, which has previously been inoculated on a general medium in a blood culture system. Currently, three continuous-reading, automated and computerized blood culture systems are available in clinical microbiology today: the Bactec 9240 (Becton Dickinson Instruments), the Bact Alert (BTH, Organon Teknika) and the Extra Sensing Power (Epic Laboratories). All of these machines measure the production-rate of a bacterium specific metabolite in the culture-bottle containing the patient's blood supplemented with general nutrient broth. Subsequently if bacterial metabolic activity is detected, the positive blood culture sample is plated on appropriate selective media for further analysis. Microbial identification, taking the positive blood culture as a starting point, takes 24 h to 72 h to complete. Reduction of the analysis time may result in reduction of the use of broad-spectrum antibiotics as the genus or species of a pathogen gives an indirect indication of the most appropriate antibiotic. Subsequently, this may result in a lower frequency of emergence of resistance against broad-spectrum antibiotics. Furthermore, it may result in lower cost because suppressive empiric therapy may be substituted by tailored and less expensive antibiotics with a smaller spectrum. Several methods for rapid detection of pathogens in human blood have been described previously, most of them using the polymerase chain reaction or fluorescently labeled probes. Although these methods are fast and accurate, routine bacteriological analysis still heavily relies on classical culturing techniques. It was therefore decided that for a molecular biological method to be successfully implemented in routine bacteriology it should be fast (maximally 1-4 h) and very easy-to-use (e.g. as complex as the preparation of a Gram-stained slide). A



oligonucleotide primer, was developed and validated. The probes described in this further practical application section comprise of single strain oligonucleotides labelled with fluorescein iso-thiocyanate at the 5'-end; complementary to a genus- or species-specific sequence on the 16S- or the 23S ribosomal RNA of the target-organism.

## Materials and methods

### 10 Blood samples

During the time of this study a total of 132 blood samples which tested positive in the BactAlert-blood culture machine were processed simultaneously, using both whole-cell hybridization and accepted culturing methods.

### Culturing

Microorganisms cultivated from positive blood cultures were identified by using the API-testsystem (BioMerieux, France) or by using standard microbiological methods.

### Probes

25 The characteristics of the probes used in this study are listed in Table 3. All probes consist of a single stranded oligonucleotide sequence covalently linked with fluorescein iso-thiocyanate at the 5'-end. Probes were synthesized by Eur. Genet. BV (Maastricht, The Netherlands).

Table 3. Oligonucleotide probes used for hybridization of some pathogens normally detected in blood from septic patients

Probe*	Sequence (5'-->3')	Target(s)	Preferred antibiotic**
EUB	GNEENETCCCTAGGAGT	Bacterial Kingdom	n.a.***
non-EUB	ACTTTTAUGGAGGCAAT	Negative control	n.a.
STREP	GTAGCGGTCCCTTTCTGG	Streptococcus spp.	Penicillin G
EFAEC	TTATCCCGCTCTGATGGG	Enterococcus faecalis	Amoxycillin
EFAEM	GGCACTCTCTCTTTTCCGG	Enterococcus faecium	Vancomycin
STAPH	AGAGAAACAAGCTTCTGCTCC	Staphylococcus aureus	Mucloxacillin
CNS	CGAGGCTTAGCTCCAAATGGTTAT	Catalase-negative Staphylococci	Vancomycin
ECOLI	GCAAGGTTATTAAGTTACTCCG	Escherichia coli	Amoxycillin
PSEUDAEH	GGAGCTTATCCCCCACTAT	Pseudomonas aeruginosa	Piperacillin+ aminoglycoside
ENTBAC	CATGAATCAGCAAGTGCTAAGCGCG	Enterobacterium spp	2 <sup>nd</sup> generation cephalosporin

5

\* All probes consist of single strain DNA covalently linked with fluorescein iso-thiocyanate at the 5'-end. The *E. coli*-specific probe is directed against 23S rRNA, the other probes are directed against the 16S rRNA. Probe-nomenclature consists of mnemonics instead of a formal nomenclature-system for reasons of convenience.

10

\*\* The antibiotic of first choice

\*\*\* not applicable

\*\*\*\* Limited choice from all available therapeutics. On the basis of the local epidemiological situations other therapeutics may prevail

15

### Whole cell hybridization

After gramstaining a streak-out preparation of a positive blood culture, a choice was made on the subsequent

20

permeabilization-protocol and a set of appropriate probes (Table 3.). Grampositive streptococci were permeabilized by incubating the fixed slide in a permeabilization-buffer (1 mg/ml lysozyme) during 5 min, gram-positive staphylococci

during 20 min. Gram-negative rods were not permeabilized. Other gram-morphologies were not considered in this section because of the low incidence of these groups of bacteria in septicemia. From a positive blood culture  
5 fifteen  $\mu$ l was pipetted on a glass slide and subsequently streaked out. After air-drying the slide, the cells on the slide were fixed in a 4% formaldehyde-solution in pure ethanol. After permeabilization, the cells on the slide were hybridized at 50°C. Gram-negative rods were  
10 hybridized during 45 min, gram-positive staphylococci were hybridized during 2 h and gram-positive streptococci were hybridized during 5 min. Per gram-type a different set of probes was chosen (see Table 4).

Table 4 Performance of the method

Application-criterion*	Probe	Target organism	n**	r***
Each assay	EUB	All bacteria	18	1.0
	non-EUB	Negative control	181	1
Gram-positive chains	STREI	<i>Streptococcus</i> spp.	2	1.0
	EPAEC	<i>Enterococcus faecalis</i>	10	1.0
	EPAEM	<i>Enterococcus faecium</i>	7	1.0
Gram-positive clumps	STAUR	<i>Staphylococcus Aureus</i>	13	1.0****
	CNS	Coagulase-negative <i>Staphylococci</i>	73	1.0
Gram-negative rods	ECOLI	<i>Escherichia coli</i>	23	1.0
	PSEUDAER	<i>Pseudomonas aeruginosa</i>	4	1.0
	ENTBAC	<i>Enterobacterium</i> spp.	23	1.0

\* The application criterion is the micromorphology of the pathogen in the initial gram-stain which is made after the BactAlert blood culture machine has detected microbiologic activity in the blood sample

\*\* n=number of strains positively identified by culturing

\*\*\* r=correlation coefficient. This is the number of matching identifications between FISH and traditional culturing divided by the total number of assays

\*\*\*\* Comprises of 66% of the total number of samples tested. Other samples showed no signal with the positive control probe

However, a probe (i.e. EUB-probe) positive for almost all bacteria and the reverse complementary probe (i.e. non-EUB probe) were included as a positive and negative control respectively, irrespective of the gram-type. Prior to use, probes were diluted to a concentration of 10 ng/ml in hybridization-buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2). After hybridization, the slides were rinsed during 1 min at 40°C in washing buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2, and mounted with VectaShield (Vector Laboratories, Burlingame, USA). Immediately hereafter, the slides were evaluated using an epifluorescence microscope.

The results of this section show that identification using whole-cell hybridization dramatically increases the speed of the diagnosis. In Figure 1 a typical example of the microscopic image obtained after hybridizing a blood sample obtained from a patient suffering from *Streptococcus pneumoniae* sepsis using the STREP-probe is shown. Using the described protocol, a clear-cut positive signal was obtained. Repeated microscopic evaluation by different observers confirmed the unambiguity of the interpretation of the images obtained by this method. In Table 4, the results of the study are listed. The observation that all strains hybridize positively with the EUB-probe indicates that the hybridization protocol is applicable for whole cell hybridization of the bacterial species and genera tested in this study. The negative results obtained with the non-EUB probe indicate the absence of aspecific interaction between the probe and constituents of the cellular matrix. The speed of diagnosis (after the sample is positive in the BactAlert blood culture machine) varies between 25 min (streptococci/enterococci) and 2 h (staphylococci), while routine bacteriological determination would take at least 24 h to 48 h. The advantage to the patient is obvious because, as can be read from Table 3, the clinician is able to start appropriate antimicrobial therapy within the working day instead of after 24 h to 48 h. Being able to choose the most appropriate antibiotic also diminishes the need for broad-spectrum antibiotics therewith indirectly lowering the incidence of antibiotic-resistance. In table 4 the results obtained in this section are mentioned.

#### **Broader application of the product**

In its current form the product can be used for fast

other clinical samples. Experiments using the current product (i.e. probes and protocols) in another type of clinical sample have been carried out. The sample-types were: liquor and ascites. Results indicate that application of the product in these samples is perfectly well possible. Future application include:

- New probes for other relevant species, genera
- Other types of clinical samples like: sputum, pus, urine, where generally non-septicaemic bacteria, such as *Legionella pneumophila* can be found, using a method according to the invention.

#### **Advantages of whole-cell hybridization**

- Rapid diagnosis enabling the clinician to easily choose the appropriate antibiotic
- Less use of broad spectrum antibiotics, therewith lowering the incidence of antibiotic resistance
- Cheap, a typical FISH-analysis is about 50% cheaper than a traditional culturing-based analysis.
- Easy to perform. A FISH-based analysis requires less actions and less hands-on time than a gram stain

#### **Lay-out of kits**

There are many possibilities for possible kit formats, several are listed below.

- One main kit for 10 Tests: 1 test is 1 positive control, 1 negative control and one unknown consisting of all kits 1-4 listed below including a detailed protocol. Or the kits listed below alone or in a combination.

Kit 1 (the control kit):

- Lyophilized positive control probe (such as EUB or probe(s) functionally related thereto)
- 5 - Lyophilized negative control probe (such as non-EUB or probe(s) functionally related thereto)
- Lyophilized hybridization buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2)

10 Kit 2 for gram-negative samples:

- Lyophilized probe such as ECOLI, PSEUDAER, ENTBAC or probe(s) functionally related thereto
  - Lyophilized hybridization buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2)
- 15

Kit 3 for gram-positive streptococci-like bacteria:

- Lyophilized probes such as STREP, EFAEC, EFAEM or probe(s) functionally related thereto
- 20 - Lyophilized hybridization buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2) with 1 mg/ml hen-eggwhite lysozyme.

25 Kit 4 for staphylococci-like bacteria:

- Lyophilized probes such as STAUR, CNS or probe(s) functionally related thereto
  - Lyophilized hybridization buffer (20 mM Tris-HCl, 0.9M NaCl, 0.1% SDS, pH 7.2) with 1<sup>0</sup> units/ml lysostaphin
- 30

Basic labeling of probes is with fluorescein iso-thio cyanate. Alternatively kits may contain probes with other fluorescent labels e.g. Cy-3, Cy5, Cy6, Cy7, Cy8, Cy9, Cy10, Cy11, Cy12, Cy13, Cy14, Cy15, Cy16, Cy17, Cy18, Cy19, Cy20, Cy21, Cy22, Cy23, Cy24, Cy25, Cy26, Cy27, Cy28, Cy29, Cy30, Cy31, Cy32, Cy33, Cy34, Cy35, Cy36, Cy37, Cy38, Cy39, Cy40, Cy41, Cy42, Cy43, Cy44, Cy45, Cy46, Cy47, Cy48, Cy49, Cy50, Cy51, Cy52, Cy53, Cy54, Cy55, Cy56, Cy57, Cy58, Cy59, Cy60, Cy61, Cy62, Cy63, Cy64, Cy65, Cy66, Cy67, Cy68, Cy69, Cy70, Cy71, Cy72, Cy73, Cy74, Cy75, Cy76, Cy77, Cy78, Cy79, Cy80, Cy81, Cy82, Cy83, Cy84, Cy85, Cy86, Cy87, Cy88, Cy89, Cy90, Cy91, Cy92, Cy93, Cy94, Cy95, Cy96, Cy97, Cy98, Cy99, Cy100.

with different fluorescent labels for simultaneous  
detection of different targets with one test. We have  
successfully detected streptococci and enterococci in one  
sample in this way. In Fig 2 an example of this type of  
5 application is shown. Here, a mixed infection of  
morphologically indistinguishable gram-positive  
streptococcus-like bacteria are successfully hybridized  
with both the STREP-probe (FITC-label) and the EFAEC-probe  
(Cy3-label). Other combinations of the above kits may also  
10 be provided as one kit for a specific application.



### Legends

Figure 1: Cells of *Streptococcus pneumoniae* show intense bright fluorescence after 1 min. of incubation with the STREP-probe at 50°C. Magnification = 10x100, fluorochrome = fluorescein iso-thiocyanate

Figure 2: Mixed infection with *E. faecalis* and *S. pneumoniae* hybridized simultaneously with both the STREP-probe (FITC-label) and the EFAECAL-probe (Cy3-label). Also a fluorescent DNA/RNA stain (DAPI) has been applied to detect all nucleic acid.

CLAIMS

1. A method for determining a bacterium suspected of being present in a sample comprising
  - a. testing said sample by Gram-staining and
  - b. testing said sample with a probe according to an in situ hybridisation protocol selected on the basis of the outcome of said Gram-staining.
2. A method according to claim 1 wherein said sample is a clinical sample.
3. A method according to claim 2 wherein said sample is mammalian blood, preferably being derived from a human.
4. A method according to claim 1, 2 or 3 wherein said Gram-staining indicates the presence of a Gram-negative bacterium in said sample, further comprising determining the rod or coccus character of said bacterium.
5. A method according to claim 4 wherein said character is of the rod type, further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found in *Escherichia coli*, in *Klebsiella pneumoniae*, in *Klebsiella oxytoca*, in *Serratia marcescens*, in *Enterobacter aerogenes*, in *Enterobacter cloacae*, in *Proteus vulgaris*, in *Proteus mirabilis*, in *Salmonella typhi*, in *Pseudomonas aeruginosa*.
6. A method according to claim 5 wherein said nucleic acid is ribosomal RNA.
7. A method according to claim 6 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCGTCCGAGTTTCGAATG or CTAGCCCTACTCGTAAGG or GATTAAGGATTAACCTTTACTCG or

sample to treatment with a lysis buffer comprising lysozyme.

9. A method according to claim 1, 2 or 3 wherein said Gram-staining indicates the presence of a Gram-positive bacterium in said sample, further comprising determining the rod or coccus character of said bacterium.

10. A method according to claim 9 wherein said character is of the rod type, further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme and/or Proteinase K.

11. A method according to claim 9 wherein said character is of the coccus type, further comprising determining a chain-like or clump-like character of said bacteria.

12. A method according to claim 11 wherein said character is chain-like, further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme.

13. A method according to claim 12 further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found in *Enterococcus faecalis*, in *Streptococcus pneumoniae*, in *Streptococcus mitis*, in *Streptococcus viridans*, in *Streptococcus sanguis*, in *Enterococcus faecium*.

14. A method according to claim 13 wherein said nucleic acid is ribosomal RNA.

15. A method according to claim 14 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence TTATCCCCCTCTGATGG or AGAGAAGCAAGCTTCCTGTCGG or GGCACCTCTCTTTTTCGG.

16. A method according to claim 11 wherein said character is clump-like, further comprising subjecting said sample to treatment with a lysis buffer comprising lysostaphin and/or Proteinase K.

- from a group of probes capable of hybridising with nucleic acid found in *Staphylococcus aureus*, in *Staphylococcus haemolyticus*, in *Staphylococcus saprophyticus*.
18. A method according to claim 17 wherein said nucleic acid is ribosomal RNA.
19. A method according to claim 18 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCTAATGCAAGCGGATCC or
- 10 CCGAAGGGGAAGGCTCTA or AGAGAAGCAAGCTTCTCGTCCGTT.
20. A method according to any of claims 4 to 19 further comprising hybridising said sample with at least one positive control probe and/or with at least one negative control probe.
- 15 21. A method according to claim 20 wherein said positive control probe comprises no more than five mismatches with a probe with the sequence GCTGCTCTCCCTAGGAGT and/or wherein said negative control probe comprises no more than five mismatches with a probe with the sequence
- 20 ACTCCTACGGGAGGCAGC.
22. A method according to anyone of claims 1 to 21 further comprising a one-step procedure to bind bacteria present in said sample to a microscopic slide and simultaneously fix intracellular structures.
- 25 23. A method according to anyone of claims 1 to 22 wherein said probe is selected for its reactivity with one or a group of bacterial genera and/or species having congruent susceptibility to antibiotic treatment.
24. A probe detecting or identifying a bacterium in a sample, preferably a clinical sample, said probe capable
- 30 of hybridising with nucleic acid found in a group of bacterial genera and/or subspecies having congruent susceptibility to antibiotic treatment.
25. A probe according to claim 24 wherein said probe is

probes having a sequence GCCTGCCAGTTTCTGAATG or  
GTAGCCCTACTCGTAAGG or GAGCAAAGSTATTAAGTTTACTCGG or  
GTTAGCCGTCCTTTCTGG or TTATCCCCCTCTGATGGG or  
AGAGAAGCAAGCTTCTCGTCCG or GCGACTCCTCTTTTTCGGG or  
5 GCTAATGCAGCGCGGATCC or CCGAAGGGGAAGGCTCTA or  
AGAGAAGCAAGCTTCTCGTCCGTT.

26. A diagnostic test kit comprising means for detecting  
or identifying a bacterium suspected of being present in a  
sample using a method according to anyone of claims 1 to  
10 23 or using a probe according to claim 24 or 25.





Figure 1: Streptococci in blood (10x100)



PCT/NL 99/00223

IPC 6 C1201/68 C1201/04

IPC 6 C120

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 277 237 A (TORAY INDUSTRIES) 10 August 1988 (1988-08-10) the whole document ---	1-23
Y	WO 93 24659 A (MICROPROBE CORP) 9 December 1993 (1993-12-09) page 2 - page 3: claim 1 ---	1-23
Y	FR 2 659 981 A (VEF SA) 27 September 1991 (1991-09-27) see abstract: claim 1 ---	1-23
Y	EP 0 479 117 A (HOFFMANN LA ROCHE) 8 April 1992 (1992-04-08) the whole document ---	1-23
	---	

Patent family members are listed in annex

3. document member of the same patent family

230

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 99/00223

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
X	WO 97 05282 A (UNIV GRONINGEN ;WELLING GJALT WIETZE (NL); SCHUT FREDERIK (NL); LA) 13 February 1997 (1997-02-13)	24,25
Y	page 2 - page 3, ln 16; pages 12 and 13; claim 7.	1-23



## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/NL 99/00223

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0277237	A	10-08-1988	WO 8800618 A	28-01-1988
WO 9324659	A	09-12-1993	AU 4396793 A	30-12-1993
			EP 0672183 A	20-09-1995
			US 5700636 A	23-12-1997
			US 5654418 A	05-08-1997
			US 5776694 A	07-07-1998
FR 2659981	A	27-09-1991	NONE	
EP 0479117	A	08-04-1992	AU 657491 B	16-03-1995
			AU 8489591 A	09-04-1992
			CA 2052822 A	06-04-1992
			JP 6090799 A	05-04-1994
			US 5620847 A	15-04-1997
			US 5635348 A	03-06-1997
WO 9705282	A	13-02-1997	AU 6631696 A	26-02-1997
			EP 0842298 A	20-05-1998